QNCX (Quince Therapeutics) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

QNCX Quince Therapeutics Inc QNCX
24 GF Score
Price $31.50
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Quince Therapeutics Valuation Rank Related Terms

QNCX
24GF Score
Quince Therapeutics Inc QNCX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
24GF Score

Get the complete analysis for QNCX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.50
Price